Cogent Biosciences, Inc. — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021. Cogent is a clinical-stage biotechnology company developing precision therapies for genetically defined diseases. Its lead program, CGT9486, is a selective KIT inhibitor being developed for systemic mastocytosis and gastrointestinal stromal tumors (GIST). The company reported no approved products or product-sales revenue.
Financial performance and liquidity
| Metric | Q1 2021 | Q1 2020 / comparison |
|---|---|---|
| Collaboration revenue | $0 | $7.0 million |
| Research and development expense | $8.2 million | $9.5 million |
| General and administrative expense | $4.6 million | $3.7 million |
| Total operating expenses | $12.8 million | $13.2 million |
| Net loss | $11.7 million | $6.1 million |
| Net loss per share, basic and diluted | $0.34 | $0.81 |
| Cash used in operating activities | $11.4 million | $7.9 million |
Amounts are in U.S. dollars. There was no product revenue, so product margins are not applicable; the filing does not provide a clear gross-margin measure. Cash and cash equivalents were $230.7 million at March 31, 2021, versus $242.2 million at year-end 2020. Current assets were $232.1 million and current liabilities were $8.2 million. The company had $1.3 million of restricted cash and $4.7 million of operating lease liabilities. No conventional borrowings are reported.
Cash, cash equivalents and restricted cash decreased by $11.5 million during the quarter. Financing activities used $0.1 million, principally for a partial CVR settlement; there were no investing cash flows. Stockholders’ equity was $226.8 million, and accumulated deficit was $210.4 million.
Material changes and unusual items
- Revenue fell by $7.0 million year over year because the Seagen collaboration had been terminated in January 2020 and all remaining collaboration revenue was recognized in 2020.
- R&D expense declined by $1.3 million, reflecting the wind-down of legacy cell-therapy work and the 2020 workforce reduction, partly offset by CGT9486 development costs. G&A expense increased by $0.9 million, primarily due to higher stock-based compensation and facility costs.
- The net loss increased by $5.6 million despite lower operating expenses, mainly because the prior-year quarter included collaboration revenue. Q1 2021 other income included $0.6 million of sublease income and $0.3 million of income from a decrease in the fair value of the contingent value right (CVR) liability.
- During the quarter, the company issued 212,429 common shares and paid $0.1 million toward the CVR obligation; the liability was $3.1 million at quarter-end. Series A preferred holders converted 18,409 shares into 4.6 million common shares during the quarter. Share-count comparisons are also affected by the 2020 financing and recapitalization.
Outlook, management commentary and risks
- Management expects to advance CGT9486 in systemic mastocytosis and GIST. The filing says the Phase 2 AdvSM study remained on track to begin in the first half of 2021; a GIST study was planned for the second half of 2021; and a Non-AdvSM trial was anticipated in the second half, subject to regulatory feedback.
- Management cited earlier CGT9486 trial results in 15 heavily pretreated GIST patients receiving CGT9486 with sunitinib: a confirmed 20% objective response rate and estimated median progression-free survival of 12 months. These are results from a small patient group, not evidence of approval or established efficacy.
- The filing contains different cash-runway statements: the financial-statement note says cash is expected to cover operating expenses and capital requirements for at least 12 months from issuance, while MD&A says existing cash is expected to fund operations into 2024. Management cautions that its estimate depends on assumptions and that additional funding will be required to complete planned development.
- Key risks include clinical and regulatory uncertainty, the timing and cost of trials, potential financing needs and dilution, manufacturing and supply constraints, competition, intellectual-property protection, and possible COVID-19-related disruption. The company reported no material COVID-19 impact as of March 31, 2021, but future effects remained uncertain.
- The company expects continuing operating losses and does not expect product revenue for several years, if ever. No material changes to the risk factors in its 2020 Form 10-K were reported. Management concluded disclosure controls were effective; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Reconcile the filing’s differing cash-runway statements and assess the assumptions behind the “into 2024” estimate.
- Track enrollment, safety, efficacy, regulatory feedback and timing for CGT9486 studies in AdvSM, Non-AdvSM and GIST.
- Evaluate the small, historical GIST combination dataset separately from results of planned prospective trials.
- Monitor quarterly cash burn, R&D spending, remaining CVR payments and potential financing needs; the company had shelf and at-the-market equity capacity but reported no sales under the sales agreement as of March 31, 2021.
- Assess potential dilution from preferred-stock conversion and equity awards, including options subject to stockholder approval.